NewLimit Stock
| Valuation | $3.1B1 |
| Valuation Date | Jun 2, 2026 |
| Implied Valuation | $2.88B |
| Last Price | $14.91 |
| 52-Week High | $22.68 |
| 52-Week Low | $12.28 |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $682.25M2 |
| Latest Round Amount | $435M3 |
| Latest Round | Series C |
| Funding Rounds | 5 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About NewLimit
NewLimit is a biotechnology company developing medicines that reverse the age of human cells through epigenetic reprogramming. It designs combinations of transcription factors with an AI system called Ambrosia, tests thousands of those combinations in parallel using a barcoded screening method it calls RESTORE-seq and reads the results with single cell sequencing to see which payloads make old cells look and behave young. The resulting therapies are mRNA payloads delivered in lipid nanoparticles, with programs aimed at the liver, the vasculature and the immune system. NewLimit has no product revenue and is funded by venture capital. It intends to make money by selling reprogramming medicines once they clear clinical trials, starting with a liver therapy it plans to put into a first human trial in 2027 in patients with fatty liver disease. The company was co-founded by Coinbase chief executive Brian Armstrong.
Invest in NewLimit
NewLimit is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
Related Companies
News
2026 May // June Progress Update
NewLimit reports that it moved its lead liver candidate through a manufacturing scale-up, closed its Series C and discovered the first reprogramming payloads that restore youthful function in old endo...
2026 Progress Update
NewLimit's mid-year update shares additional preclinical data on its first candidate medicine, which restores youthful function in liver hepatocytes and improves their resilience to damage and their a...
NewLimit snags $435M after seeing age reversal in human liver cells
BioSpace reports on NewLimit's $435 million Series C, led by Founders Fund with Thrive Capital, Greenoaks, Quiet Capital and Eli Lilly Ventures. The financing follows lab results showing the company's...
NewLimit raises $435M Series C, valuation hits $3.1B
Quartz reports that NewLimit's Series C valued the anti-aging startup at $3.1 billion, more than triple its worth twelve months earlier. It was the company's third financing in roughly a year.
NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trials
NewLimit closed a $435 million Series C led by Founders Fund and plans to bring its first aging-reprogramming liver therapy into human clinical trials in 2027.
Longevity startup NewLimit raises $435 million for clinical trials
NewLimit closed a $435 million Series C at a $3.1 billion valuation led by Founders Fund and plans its first human clinical trial of a liver reprogramming therapy in 2027.
NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trials
NewLimit announced a $435 million Series C led by Founders Fund, with new investors Thrive Capital, Greenoaks and Quiet Capital joining returning backers including Kleiner Perkins and Eli Lilly Ventur...
Anti-aging biotech NewLimit raises $435M at $3B+ valuation
Endpoints News reports the round closed at a $3.1 billion post-money valuation, one of the largest private biotech financings of 2026. It notes the clinical timeline moved up sharply from CEO Jacob Ki...
No limits: NewLimit lands $435m ahead of human trials
Longevity.Technology covers the Series C and reports that NewLimit's first clinical study is expected to enrol people with fatty liver disease. The company says its lead therapy reversed cellular age ...
Can You Reverse Decades of Drinking Damage? Perhaps. - EP 75 Jacob Kimmel Is Back
NewLimit co-founder and CEO Jacob Kimmel discusses the company's liver reprogramming results in aged mice, the Ambrosia AI system and the design of the planned first human trial.
January // February 2026 Progress Update
NewLimit moved its first candidate medicine into large-scale manufacturing and reported a second payload that restores multiple youthful functions in old hepatocytes. It also said a new AI system doub...
2025 Year in Review
NewLimit's annual review describes building its first preclinical candidate, a payload that restored youthful gene expression, regenerative capacity and alcohol resilience in a humanized liver model w...
September // October 2025 Progress Update
NewLimit reported testing more than 3,000 transcription factor sets across its programs and a fivefold decrease in molecular construction costs, alongside new hires to lead its immunology therapeutic ...
NewLimit has raised an additional $45M from Lilly, Duke University, Section 32, & Abstract on a $1.62B cap
Five months after its Series B, NewLimit raised a further $45 million on a $1.62 billion cap from Eli Lilly, Duke Management Company, Section 32 and others, with insiders including Kleiner Perkins and...
July // August 2025 Progress Update
NewLimit reported higher discovery rates from its reprogramming AI, its first lead payload with translational chemistry and its first screens in endothelial cells.
Matthew Breyer and Benjamin Humphreys have joined our Scientific Advisory Board
NewLimit added nephrology researchers Matthew Breyer, a former Eli Lilly and Janssen executive, and Benjamin Humphreys of Washington University in St. Louis to its scientific advisory board.
NewLimit, founded by Coinbase CEO Brian Armstrong, raises $130M to develop age-reversing treatments
TechCrunch reports NewLimit's $130 million Series B led by Kleiner Perkins. CEO Jacob Kimmel said the company had discovered three prototype medicines that reprogram liver cells and restore their abil...
Kleiner Perkins leads $130M round in Coinbase founder's antiaging startup, NewLimit
Fortune interviews Brian Armstrong about the Series B and NewLimit's epigenetic reprogramming approach. At the time the company planned non-human primate testing within a year or two and human testing...
NewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and others
NewLimit announced a $130 million Series B led by Kleiner Perkins, with Nat Friedman and Daniel Gross, Khosla Ventures, Human Capital and Valor Equity Partners joining existing investors Dimension, Fo...
Human Life Extension Startup NewLimit Raises New Funding Round
Bloomberg reports that the Series B valued NewLimit at $810 million, the first valuation the company had disclosed.
NewLimit, cofounded by Coinbase CEO Brian Armstrong, raises $40M to extend life
NewLimit, a 1.5-year-old, San Francisco-based, 17-person company that aims to increase the number of healthy years each person lives by epigenetically reprogramming cells, is today announcing that it ...